HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥Association of Biomarkers With Efficacy in the Phase 3 KEYNOTE-671 Study of Perioperative Pembrolizumab (Pembro) Plus Neoadjuvant Chemotherapy (Chemo) in Early-Stage Non–Small-Cell Lung Cancer (NSCLC) 🎙️ @marinagarassino 🔢2519O 🎯Higher TMB Associated With Better EFS (p=0.000164) and OS (p=0.005) With Pembro 🎯Pembro Benefit Over Chemo Consistent Regardless of T-cell-inflamed GEP, TMB, or KRAS Status ☑️NCT03425643 🔗 https://t.co/grEfaUbJVf @OncoAlert @Larvol @myESMO @IASLC
热度 3 · 3 赞 · 0 回复 · 0 转发
会议摘要
NCT03425643NCT03425643按 - **标题 / Title：** Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) 对上
- **标题 / Title：** Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)读摘要原文 →来源：HHorinouchi · x.com